Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News — For high-risk patients with mild-to-moderate COVID-19 during the omicron epoch, bebtelovimab seems to be a reliable treatment option, according to a study published online September 17 in the Journal of Infectious Diseases.
Raymund R. Razonable, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective cohort study involving 3607 high-risk patients to examine the effectiveness of bebtelovimab in real-world settings. A total of 2833 patients received bebtelovimab and 774 received nirmatrelvir-ritonavir.
The researchers found that compared with nirmatrelvir-ritonavir, bebtelovimab was used more often for treatment of COVID-19 among older patients, immunosuppressed patients, and those with multiple comorbidities. The rates of progression to severe disease by 30 days after treatment were not significantly different after bebtelovimab vs nirmatrelvir-ritonavir treatment (1.4 vs 1.2%). The rate of admission to the intensive care unit was comparable between the groups (0.5 and 0.3% for those receiving bebtelovimab and nirmatrelvir-ritonavir treatment, respectively).
“This study gives us confidence that bebtelovimab is reliable for the treatment of high-risk patients during this omicron epoch characterized by increasingly new variants, and gives us another tool in the effort against COVID-19,” Razonable said in a statement.
Two authors disclosed financial ties to the pharmaceutical industry.
